Answers are grounded in this paper and cite their sources.
< 0.001). Additionally, other glucose outcomes including time above range (> 10.0 mmol/L) and median blood glucose were significantly improved in the FCL treatment period. To conclude, this trial provides preliminary evidence that treatment with the bihormonal FCL system may improve glucose outcome parameters, with no safety concerns observed in adolescents with Type 1 diabetes over the short study duration. However, future research should focus on long-term trials with larger study populations to confirm these findings and evaluate the long-term effects of bihormonal FCL treatment in adolescents.
No takes yet. Share an insight, caveat, or question.
Booijink et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: